Citations

Citations to this article as recorded by  

• Combining Ezetimibe and Rosuvastatin: Impacts on Insulin Sensitivity and Vascular Inflammation in Patients with Type 2 Diabetes Mellitus
  Eun Roh
  Diabetes & Metabolism Journal.2024; 48(1): 55.     CrossRef

Citations

Citations to this article as recorded by  

• Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
  Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
  Metabolism.2024; 152: 155789.     CrossRef
• Letter by In-Kyung Jeong Regarding Article, Trends in Prevalence of Hypertriglyceridemia and Related Factors in Korean Adults: A Serial Cross-Sectional Study
  In-Kyung Jeong
  Journal of Lipid and Atherosclerosis.2024; 13(1): 80.     CrossRef
• Association between cardiovascular disease risk and incident type 2 diabetes mellitus in individuals with prediabetes: A retrospective cohort study
  Myung Jin Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee
  Diabetes Research and Clinical Practice.2024; 208: 111125.     CrossRef
• Korea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations
  Hyeon Chang Kim, Hokyou Lee, Hyeok-Hee Lee, Dasom Son, Minsung Cho, Sojung Shin, Yeeun Seo, Eun-Jin kim, Song Vogue Ahn, Sun Ha Jee, Sungha Park, Hae-Young Lee, Min Ho Shin, Sang-Hyun Ihm, Seung Won Lee, Jong Ku Park, Il Suh, Tae-Yong Lee
  Clinical Hypertension.2024;[Epub]     CrossRef
• Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes
  Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee
  The Journal of Clinical Endocrinology & Metabolism.2024;[Epub]     CrossRef
• Effect of Adding Apolipoprotein B Testing on the Prevalence of Dyslipidemia and Risk of Cardiovascular Disease in the Korean Adult Population
  Rihwa Choi, Sang Gon Lee, Eun Hee Lee
  Metabolites.2024; 14(3): 169.     CrossRef
• A self-powered and supercapacitive microneedle continuous glucose monitoring system with a wide range of glucose detection capabilities
  Hye-Jun Kil, Jang Hyeon Kim, Kanghae Lee, Tae-Uk Kang, Ju-Hyun Yoo, Yong-ho Lee, Jin-Woo Park
  Biosensors and Bioelectronics.2024; 257: 116297.     CrossRef
• Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history
  Jin Hwa Kim, Young Sang Lyu, BongSeong Kim, Mee Kyung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon
  Diabetes, Obesity and Metabolism.2024;[Epub]     CrossRef
• Management of Dyslipidemia in Patients with Diabetes Mellitus
  Kyung Ae Lee
  The Journal of Korean Diabetes.2023; 24(3): 111.     CrossRef
• 2023 Clinical Practice Guidelines for Diabetes: Recommendations for Pharmacological Treatment of Type 2 Diabetes
  Junghyun Noh
  The Journal of Korean Diabetes.2023; 24(3): 127.     CrossRef
• 2023 Clinical Practice Guidelines for Diabetes
  Min Kyong Moon
  The Journal of Korean Diabetes.2023; 24(3): 120.     CrossRef
• 2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
  Ye Seul Yang
  The Journal of Korean Diabetes.2023; 24(3): 135.     CrossRef
• A 33-Year-Old Man Presented with Abdominal Pain and Vomiting Starting a Day Ago
  Jong Han Choi
  The Korean Journal of Medicine.2023; 98(6): 289.     CrossRef
• Comorbidity Patterns and Management in Inpatients with Endocrine Diseases by Age Groups in South Korea: Nationwide Data
  Sung-Soo Kim, Hun-Sung Kim
  Journal of Personalized Medicine.2023; 14(1): 42.     CrossRef

Citations

Citations to this article as recorded by  

• Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study
  Harmanjit Singh, Ravi Rohilla, Shivani Jaswal, Mandeep Singla
  Expert Review of Endocrinology & Metabolism.2024; 19(1): 81.     CrossRef
• Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects
  Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, Mandeep Singla, Jagjit Singh, Farideh Javid
  Expert Review of Clinical Pharmacology.2023; 16(1): 49.     CrossRef
• Mechanism of molecular interaction of sitagliptin with human DPP4 enzyme - New Insights
  Michelangelo Bauwelz Gonzatti, José Edvar Monteiro Júnior, Antônio José Rocha, Jonathas Sales de Oliveira, Antônio José de Jesus Evangelista, Fátima Morgana Pio Fonseca, Vânia Marilande Ceccatto, Ariclécio Cunha de Oliveira, José Ednésio da Cruz Freire
  Advances in Medical Sciences.2023; 68(2): 402.     CrossRef
• A prospective multicentre open label study to assess effect of Teneligliptin on glycemic control through parameters of time in range (TIR) Metric using continuous glucose monitoring (TOP-TIR study)
  Banshi Saboo, Suhas Erande, A.G. Unnikrishnan
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(2): 102394.     CrossRef
• Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes
  Min Jeong Park, Kyung Mook Choi
  Diabetes & Metabolism Journal.2022; 46(1): 49.     CrossRef

Obesity results in an inflammatory microenvironment in adipose tissue, leading to the deterioration of tissue protective mechanisms. Although recent studies suggested the importance of type 2 immunity in an anti-inflammatory microenvironment in adipose tissue, the regulatory effects of T helper 2 (Th2) cytokines on systemic metabolic regulation are not fully understood. Recently, we identified the roles of the Th2 cytokine (interleukin 4 [IL-4] and IL-13)-induced adipokine, growth differentiation factor 15 (GDF15), in adipose tissue in regulating systemic glucose metabolism via signal transducer and activator of transcription 6 (STAT6) activation. Moreover, we showed that mitochondrial oxidative phosphorylation is required to maintain these macrophage-regulating autocrine and paracrine signaling pathways via Th2 cytokine-induced secretion of GDF15. In this review, we discuss how the type 2 immune response and Th2 cytokines regulate metabolism in adipose tissue. Specifically, we review the systemic regulatory roles of Th2 cytokines in metabolic disease and the role of mitochondria in maintenance of type 2 responses in adipose tissue homeostasis.

Citations

Citations to this article as recorded by  

• Orchestration of the Adipose Tissue Immune Landscape by Adipocytes
  David Bradley, Tuo Deng, Dharti Shantaram, Willa A. Hsueh
  Annual Review of Physiology.2024; 86(1): 199.     CrossRef
• Growth and differentiation factor-15: A link between inflammaging and cardiovascular disease
  Balázs Bence Nyárády, Loretta Zsuzsa Kiss, Zsolt Bagyura, Béla Merkely, Edit Dósa, Orsolya Láng, László Kőhidai, Éva Pállinger
  Biomedicine & Pharmacotherapy.2024; 174: 116475.     CrossRef
• Evaluation of Mitochondrial Function in Blood Samples Shows Distinct Patterns in Subjects with Thyroid Carcinoma from Those with Hyperplasia
  Julia Bernal-Tirapo, María Teresa Bayo Jiménez, Pedro Yuste-García, Isabel Cordova, Ana Peñas, Francisco-Javier García-Borda, Cesar Quintela, Ignacio Prieto, Cristina Sánchez-Ramos, Eduardo Ferrero-Herrero, María Monsalve
  International Journal of Molecular Sciences.2023; 24(7): 6453.     CrossRef
• A Supportive Role of Mesenchymal Stem Cells on Insulin-Producing Langerhans Islets with a Specific Emphasis on The Secretome
  Ronit Vogt Sionov, Ronit Ahdut-HaCohen
  Biomedicines.2023; 11(9): 2558.     CrossRef
• Gdf15 deletion exacerbates acute lung injuries induced by intratracheal inoculation of aerosolized ricin in mice
  Mengyun Deng, Duo Su, Nan Xiao, Zhipeng Zhang, Yifeng Wang, Fuliang Zong, Sha Li, Jinglin Wang, Dongsheng Zhou, Yuee Zhao, Huiying Yang
  Toxicology.2022; 469: 153135.     CrossRef
• Role of PPAR Receptor and Ligands in the Pathogenesis and Therapy of Hematologic Malignancies
  Jian Wu, Min Zhang, Allison Faircloth
  Hemato.2022; 3(3): 422.     CrossRef
• Macrophage and Adipocyte Mitochondrial Dysfunction in Obesity-Induced Metabolic Diseases
  Liwen Wang, Jie Hu, Haiyan Zhou
  The World Journal of Men's Health.2021; 39(4): 606.     CrossRef
• Th2 Cytokines Increase the Expression of Fibroblast Growth Factor 21 in the Liver
  Seul-Gi Kang, Seong-Eun Lee, Min-Jeong Choi, Joon-Young Chang, Jung-Tae Kim, Ben-Yuan Zhang, Yea-Eun Kang, Ju-Hee Lee, Hyon-Seung Yi, Minho Shong
  Cells.2021; 10(6): 1298.     CrossRef
• Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint
  Jörg Wischhusen, Ignacio Melero, Wolf Herman Fridman
  Frontiers in Immunology.2020;[Epub]     CrossRef
• Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages
  Irina Larionova, Elena Kazakova, Marina Patysheva, Julia Kzhyshkowska
  Cancers.2020; 12(6): 1411.     CrossRef

Citations

Citations to this article as recorded by  

• LGR4: A New Receptor Member in Endocrine and Metabolic Diseases
  Ningning Zhang, Mingyang Yuan, Jiqiu Wang
  Endocrine Reviews.2023; 44(4): 647.     CrossRef
• R-Spondin1 and tumor necrosis factor-alpha in infertile women with polycystic ovary syndrome: relationships with insulin resistance and other parameters
  Tuğba GÜRBÜZ, Oya GÖKMEN, Asena AYAR MADENLİ, Berna DİLBAZ
  Journal of Health Sciences and Medicine.2023; 6(2): 449.     CrossRef
• An early prediction model for type 2 diabetes mellitus based on genetic variants and nongenetic risk factors in a Han Chinese cohort
  Jinjin Li, Qun Ye, Hongxiao Jiao, Wanyao Wang, Kai Zhang, Chen Chen, Yuan Zhang, Shuzhi Feng, Ximo Wang, Yubao Chen, Huailin Gao, Fengjiang Wei, Wei-Dong Li
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Emerging Therapeutic Strategies for Attenuating Tubular EMT and Kidney Fibrosis by Targeting Wnt/β-Catenin Signaling
  Lichao Hu, Mengyuan Ding, Weichun He
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Does Serum R-Spondin-1 Play a Role in PCOS Pathophysiology?
  Osman BAŞPINAR, Yasin ŞİMŞEK, Derya KOÇER, Oğuzhan Sıtkı DİZDAR, Hatice KAYIŞ TOPALOĞLU
  Genel Tıp Dergisi.2022; 32(5): 490.     CrossRef
• Silencing of RSPO1 mitigates obesity-related renal fibrosis in mice by deactivating Wnt/β-catenin pathway
  Xuesong Su, Guangyu Zhou, Mi Tian, Si Wu, Yanqiu Wang
  Experimental Cell Research.2021; 405(2): 112713.     CrossRef
• Exosome miR‐27a‐3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma
  Xuehan Fan, Jingya Wang, Tingting Qin, Yujia Zhang, Wenting Liu, Kaiting Jiang, Dingzhi Huang
  Thoracic Cancer.2020; 11(6): 1453.     CrossRef
• Integrative Analyses of Genes Associated with Subcutaneous Insulin Resistance
  Manoj Kumar Pujar, Basavaraj Vastrad, Chanabasayya Vastrad
  Biomolecules.2019; 9(2): 37.     CrossRef

We analyzed circulating soluble epidermal growth factor receptor (sEGFR) levels in humans. Serum sEGFR levels were higher in subjects with newly diagnosed type 2 diabetes mellitus compared with controls. Serum sEGFR was positively correlated with glycosylated hemoglobin and serum glucose and negatively correlated with serum insulin and C-peptide levels.

Citations

Citations to this article as recorded by  

• Increased serum extrachromosomal circular DNA SORBS1circle level is associated with insulin resistance in patients with newly diagnosed type 2 diabetes mellitus
  Xiang Kong, Shu-jun Wan, Tian-bing Chen, Lan Jiang, Yu-jie Xing, Ya-ping Bai, Qiang Hua, Xin-ming Yao, Yong-li Zhao, Hong-mei Zhang, De-guo Wang, Qing Su, Kun Lv
  Cellular & Molecular Biology Letters.2024;[Epub]     CrossRef
• A Pilot Genome-Wide Association Study Identifies Novel Markers of Metabolic Syndrome in Patients with Psoriasis
  Seung-Min Oh, Su-Kang Kim, Hye-Jin Ahn, Ki-Heon Jeong
  Annals of Dermatology.2023; 35(4): 285.     CrossRef
• Effect of cholesterol-lowering agents on soluble epidermal growth factor receptor level in type 2 diabetes and hypercholesterolemia
  Jun Choul Lee, Kyong Hye Joung, Ji Min Kim, Seon Mee Kang, Hyun Jin Kim, Bon Jeong Ku
  Medicine.2022; 101(34): e30287.     CrossRef
• Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects
  Mayu Kyohara, Jun Shirakawa, Tomoko Okuyama, Yu Togashi, Ryota Inoue, Jinghe Li, Daisuke Miyashita, Yasuo Terauchi
  Diabetology & Metabolic Syndrome.2020;[Epub]     CrossRef
• Epidermal growth factor protects against myocardial ischaemia reperfusion injury through activating Nrf2 signalling pathway
  Jun Ma, Ge Jin
  Free Radical Research.2019; 53(3): 313.     CrossRef

Citations

Citations to this article as recorded by  

• A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
  Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
  Diabetes, Obesity and Metabolism.2022; 24(9): 1800.     CrossRef
• Apparent Insulin Deficiency in an Adult African Population With New-Onset Type 2 Diabetes
  Davis Kibirige, Isaac Sekitoleko, Priscilla Balungi, William Lumu, Moffat J. Nyirenda
  Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
• Rising Incidence of Diabetes in Young Adults in South Korea: A National Cohort Study
  Hyun Ho Choi, Giwoong Choi, Hojun Yoon, Kyoung Hwa Ha, Dae Jung Kim
  Diabetes & Metabolism Journal.2022; 46(5): 803.     CrossRef
• A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
  Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Y
  Diabetes & Metabolism Journal.2022; 46(6): 855.     CrossRef
• The Potential Effect of Rhizoma coptidis on Polycystic Ovary Syndrome Based on Network Pharmacology and Molecular Docking
  Liyun Duan, De Jin, Xuedong An, Yuehong Zhang, Shenghui Zhao, Rongrong Zhou, Yingying Duan, Yuqing Zhang, Xinmin Liu, Fengmei Lian, Wen yi Kang
  Evidence-Based Complementary and Alternative Medicine.2021; 2021: 1.     CrossRef
• PRKAA2variation and the clinical characteristics of patients newly diagnosed with type 2 diabetes mellitus in Yogyakarta, Indonesia
  Dita Maria Virginia, Mae Sri Hartati Wahyuningsih, Dwi Aris Agung Nugrahaningsih
  Asian Biomedicine.2021; 15(4): 161.     CrossRef
• Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
  Jeong Mi Kim, Sang Soo Kim, Jong Ho Kim, Mi Kyung Kim, Tae Nyun Kim, Soon Hee Lee, Chang Won Lee, Ja Young Park, Eun Sook Kim, Kwang Jae Lee, Young Sik Choi, Duk Kyu Kim, In Joo Kim
  Diabetes & Metabolism Journal.2020; 44(1): 67.     CrossRef
• Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
  Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung
  Endocrinology and Metabolism.2019; 34(4): 382.     CrossRef
• Insulin Resistance versus β-Cell Failure: Is It Changing in Koreans?
  Mi-kyung Kim
  Diabetes & Metabolism Journal.2018; 42(2): 128.     CrossRef
• Response: Clinical Characteristics of People with Newly Diagnosed Type 2 Diabetes between 2015 and 2016: Difference by Age and Body Mass Index (Diabetes Metab J2018;42:137-46)
  Kyoung Hwa Ha, Dae Jung Kim, Sungrae Kim
  Diabetes & Metabolism Journal.2018; 42(3): 251.     CrossRef
• Letter: Clinical Characteristics of People with Newly Diagnosed Type 2 Diabetes between 2015 and 2016: Difference by Age and Body Mass Index (Diabetes Metab J 2018;42:137-46)
  Ah Reum Khang
  Diabetes & Metabolism Journal.2018; 42(3): 249.     CrossRef

Citations

Citations to this article as recorded by  

• International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes
  Michael Bergman, Melania Manco, Ilhan Satman, Juliana Chan, Maria Inês Schmidt, Giorgio Sesti, Teresa Vanessa Fiorentino, Muhammad Abdul-Ghani, Ram Jagannathan, Pramod Kumar Thyparambil Aravindakshan, Rafael Gabriel, Viswanathan Mohan, Martin Buysschaert,
  Diabetes Research and Clinical Practice.2024; 209: 111589.     CrossRef
• A unified technique for entropy enhancement based diabetic retinopathy detection using hybrid neural network
  Fatima, Muhammad Imran, Anayat Ullah, Muhammad Arif, Rida Noor
  Computers in Biology and Medicine.2022; 145: 105424.     CrossRef
• In-silico identification of peroxisome proliferator-activated receptor (PPAR)α/γ agonists from Ligand Expo Components database
  Xiao-Yan Feng, Ting-Ting Ding, Ya-Ya Liu, Wei-Ren Xu, Xian-Chao Cheng
  Journal of Biomolecular Structure and Dynamics.2021; 39(5): 1853.     CrossRef

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Citations

Citations to this article as recorded by  

• Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model
  Yeon Woong Chung, Ji Young Lee, Hyun Hee Ju, Jin A. Choi
  European Journal of Pharmacology.2022; 933: 175269.     CrossRef
• Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
  Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv
  Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
• Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
  Doo Soo Jeon
  Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11.     CrossRef
• The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
  Ju-Ming Lu
  Advances in Therapy.2019; 36(4): 798.     CrossRef
• A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
  Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
  Diabetes Therapy.2019; 10(1): 5.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
  Hyun Jin Kim
  The Journal of Korean Diabetes.2018; 19(1): 35.     CrossRef

The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.

Citations

Citations to this article as recorded by  

• Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
  Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Jae-Myung Yu, Hye Soon Kim, Hyun Jin Kim, Won Kim, Dong Han Kim, Hak Chul Jang
  Advances in Therapy.2024;[Epub]     CrossRef
• Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
  Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
  Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
  Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
• Effects of an actual insulin injection demonstration on insulin acceptance among patients with T2DM: a pragmatic randomized controlled trial
  Atthayaporn Choomai, Apichai Wattanapisit, Orathai Tiangtam
  Romanian Journal of Internal Medicine.2021; 59(2): 151.     CrossRef
• Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
  Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung
  Endocrinology and Metabolism.2019; 34(4): 382.     CrossRef
• Capacity and confidence building for general practitioners on optimum insulin use
  Sanjay Kalra, Prasun Deb, KalyanK Gangopadhyay, Sunil Gupta, Abhay Ahluwalia
  Journal of Family Medicine and Primary Care.2019; 8(10): 3096.     CrossRef
• Educational Strategies for Insulin Injection Therapy in Elderly Diabetic Patients
  Eun Chong Shin
  The Journal of Korean Diabetes.2018; 19(2): 101.     CrossRef
• Summary of Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
  Byung-Wan Lee
  The Journal of Korean Diabetes.2018; 19(1): 31.     CrossRef
• New anti-diabetic agents
  Doo-Man Kim
  Journal of the Korean Medical Association.2017; 60(12): 992.     CrossRef

The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

Citations

Citations to this article as recorded by  

• Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications
  Neha V. Bhilare, Rushikesh Shedge, Prashant M. Tambe, Ajinkya More
  Medicinal Chemistry Research.2024; 33(3): 337.     CrossRef
• Simultaneous Estimation of Repaglinide and Voglibose in Newly Approved Fixed-Dose Combination by using UFLC: Application to ICH Q14 Concept and Comparative Method Greenness Assessment
  S.S. Panda, P.C. Rauta, V.S. Pulusu, S. Sahu, B.B. Dash
  Asian Journal of Chemistry.2023; 35(4): 887.     CrossRef
• Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
  Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya, Kumar Gaurav
  International Journal of Diabetes in Developing Countries.2023; 43(6): 856.     CrossRef
• The Gut Microbiome, Metformin, and Aging
  Sri Nitya Reddy Induri, Payalben Kansara, Scott C. Thomas, Fangxi Xu, Deepak Saxena, Xin Li
  Annual Review of Pharmacology and Toxicology.2022; 62(1): 85.     CrossRef
• Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial
  Wajiha Mahjabeen, Dilshad Ahmed Khan, Shakil Ahmed Mirza
  Complementary Therapies in Medicine.2022; 66: 102819.     CrossRef
• Letrozole: Pharmacology, toxicity and potential therapeutic effects
  Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Dhanushya Nagarajan, Vibhaa K K, Anagha V, Joshua Paul P, Tharani Priya T, Rituraj Chakraborty, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Abilash Valsala Gopalakrishnan
  Life Sciences.2022; 310: 121074.     CrossRef
• Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
  Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
  Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
• Treatment intensification in type 2 diabetes management after the failure of two oral hypoglycemic agents: A non‐interventional comparative study
  Sirajudeen Shaik Alavudeen, Sultan M. Alshahrani, Easwaran Vigneshwaran, Noohu Abdulla Khan, Javid I. Mir, Abubakr T. M. Hussein
  International Journal of Clinical Practice.2021;[Epub]     CrossRef
• Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus
  Antonios Kousaxidis, Anthi Petrou, Vasiliki Lavrentaki, Maria Fesatidou, Ioannis Nicolaou, Athina Geronikaki
  European Journal of Medicinal Chemistry.2020; 207: 112742.     CrossRef
• Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86)
  Hannah Seok, Tae Seo Sohn
  Diabetes & Metabolism Journal.2019; 43(4): 545.     CrossRef
• A Survey of the Structures of US FDA Approved Combination Drugs
  Pradipta Das, Michael D. Delost, Munaum H. Qureshi, David T. Smith, Jon T. Njardarson
  Journal of Medicinal Chemistry.2019; 62(9): 4265.     CrossRef
• Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate and repaglinide in tablets
  Marianne A. Mahrouse, Nesrine T. Lamie
  Microchemical Journal.2019; 147: 691.     CrossRef
• The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea
  Da Young Lee, Ji Hee Yu, Sanghyun Park, Kyungdo Han, Nam Hoon Kim, Hye Jin Yoo, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim, Ji A. Seo
  Scientific Reports.2018;[Epub]     CrossRef
• Effect of Lifestyle Modification and Oral Anti-Diabetic Drugs on Metabolic Parameters in Recently Diagnosed Patientswith Uncomplicated Type 2 Diabetes Mellitus in Eastern India
  Nikhilesh Pradhan, Sidhartha Das, Anoj Kumar Baliarsinha, Ashirbad Parhi, Bijan Patnaik, Pramod Kumar Rout
  Journal of Diabetes Mellitus.2018; 08(02): 9.     CrossRef
• Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program
  Ja Young Jeon, Soo Jin Lee, Sieun Lee, Soo Jin Kim, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Young Seol Kim, Jeong Taek Woo, Kyu Jeung Ahn, Moonsuk Nam, Sei Hyun Baik, Yongsoo Park, Kwan‐Woo Lee
  Journal of Diabetes Investigation.2018; 9(5): 1144.     CrossRef

In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly.

Citations

Citations to this article as recorded by  

• Diabetic Patients with COVID-19 Complications: Insights into Prevalence, Prognosis, Combination Medications, and Underlying Mechanisms
  Pranay Wal, Jyotsana Dwivedi, Ankita Wal, Shivangi Kushwaha
  Current Diabetes Reviews.2023;[Epub]     CrossRef
• Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
  Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
  Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
• Synthesis, antidiabetic activity and molecular docking study of rhodanine-substitued spirooxindole pyrrolidine derivatives as novel α-amylase inhibitors
  Amani Toumi, Sarra Boudriga, Khaled Hamden, Mansour Sobeh, Mohammed Cheurfa, Moheddine Askri, Michael Knorr, Carsten Strohmann, Lukas Brieger
  Bioorganic Chemistry.2021; 106: 104507.     CrossRef
• Clinical Impact of Combination Therapy in Diabetic Neuropathy and Nephropathy
  Harmeet Kaur, Arvinder Kaur, Pankaj Kumar Prashar, Anamika Gautam, Ankita Sood, Sachin Kumar Singh, Monica Gulati, Narendra Kumar Pandey, Bimlesh Kumar
  Research Journal of Pharmacy and Technology.2021; : 3471.     CrossRef
• Type II diabetes mellitus: a review on recent drug based therapeutics
  Santwana Padhi, Amit Kumar Nayak, Anindita Behera
  Biomedicine & Pharmacotherapy.2020; 131: 110708.     CrossRef
• Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)
  Soo Heon Kwak, You‐Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang‐Yong Kim, Jae Hyeon Kim
  Diabetes, Obesity and Metabolism.2020; 22(2): 173.     CrossRef
• Metabolomics approach to identify the active substances influencing the antidiabetic activity of Lagerstroemia species
  Mun-Ock Kim, Su Ui Lee, Heung Joo Yuk, Hyun-Jae Jang, Jae-Won Lee, Eun-Bin Kwon, Jin-Hyub Paik, SangHo Choi, Adek Nizar, Tran The Bach, Kongmany Sydara, Hang Jin, So-Yeun Woo, Sei-Ryang Oh, Hyung Won Ryu
  Journal of Functional Foods.2020; 64: 103684.     CrossRef
• Cardiometabolic diseases and active aging - polypharmacy in control
  Adriana Nancy Medeiros dos Santos, Dulcineia Rebecca Cappelletti Nogueira, Beatriz Aparecida Ozello Gutierrez, Rosa Yuka Sato Chubaci, Caroline Ribeiro de Borja Oliveira
  Revista Brasileira de Enfermagem.2020;[Epub]     CrossRef
• Anti-Diabetic Nephropathy Activities of Polysaccharides Obtained from Termitornyces albuminosus via Regulation of NF-κB Signaling in db/db Mice
  Chang Yang, Qi Feng, Huan Liao, Xinlei Yu, Yang Liu, Di Wang
  International Journal of Molecular Sciences.2019; 20(20): 5205.     CrossRef
• Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes
  Min Joo Kim, Mi Na Kim, Se Hee Min, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung
  Metabolism.2019; 97: 87.     CrossRef
• A randomized, open‐label, multicentre, parallel‐controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti
  Lixin Guo, Li Chen, Baocheng Chang, Liyong Yang, Yu Liu, Bo Feng
  Diabetes, Obesity and Metabolism.2018; 20(12): 2740.     CrossRef
• Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association
  Sang Youl Rhee
  The Journal of Korean Diabetes.2018; 19(1): 15.     CrossRef

In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

Citations

Citations to this article as recorded by  

• Comparative Study on Efficacy of Empagliflozin Versus Sitagliptin, as an Add-on Therapy to Metformin in Type 2 Diabetic Patients
  Harsh Salankar, Sonali Rode, C. Arjun, Rajeeta Joseph, Gourav B. Deshmane, Radhika P. Vijayan
  Journal of Pharmacy and Bioallied Sciences.2024; 16(Suppl 1): S335.     CrossRef
• Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
  Young-Hwan Park, Minji Sohn, So Yeon Lee, Soo Lim
  Diabetes & Metabolism Journal.2024; 48(2): 253.     CrossRef
• Association of preoperative blood glucose level with delirium after non-cardiac surgery in diabetic patients
  Soo Jung Park, Ah Ran Oh, Jong-Hwan Lee, Kwangmo Yang, Jungchan Park
  Korean Journal of Anesthesiology.2024; 77(2): 226.     CrossRef
• Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
  R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
  Journal of Endocrinological Investigation.2023; 46(5): 855.     CrossRef
• Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study
  Hyeong Kyu Park, Kyoung‐Ah Kim, Kyung‐Wan Min, Tae‐Seo Sohn, In Kyung Jeong, Chul Woo Ahn, Nan‐Hee Kim, Ie Byung Park, Ho Chan Cho, Choon Hee Chung, Sung Hee Choi, Kang Seo Park, Seoung‐Oh Yang, Kwan Woo Lee
  Diabetes, Obesity and Metabolism.2023; 25(9): 2743.     CrossRef
• Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection
  Jong Chul Won
  The Journal of Korean Diabetes.2023; 24(2): 59.     CrossRef
• A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation
  Mazhar Ahmed, Asjad Saeed, Muhammad Zarar Khan, Sana Z Javaid, Farhan Aslam, Savida Ilyas Dar
  Cureus.2023;[Epub]     CrossRef
• Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extensio
  Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
  Diabetes & Metabolism Journal.2023; 47(6): 808.     CrossRef
• Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Study
  Ling Qu, Xiao-chun Liang, Guo-qing Tian, Gai-li Zhang, Qun-li Wu, Xiu-mei Huang, Ya-zhong Cui, Yu-ling Liu, Zhu-fang Shen, Guo-qing Ma, Hao Lu, Yi Li, Hong Jiang, Xi-yan Yang, Guang-de Zhang, Chen-hua Yang
  Chinese Journal of Integrative Medicine.2022; 28(4): 304.     CrossRef
• Risk for Imbalanced Blood Glucose Pattern: Construct Analysis and Nursing Diagnosis Proposal
  Rafael Oliveira Pitta Lopes, Jéssica de Castro Santos, Hudson Carmo de Oliveira, Juliana Faria Campos, Cândida Caniçali Primo, Camila Takáo Lopes, Marcos Antônio Gomes Brandão
  Clinical Nursing Research.2022; 31(7): 1241.     CrossRef
• Long‐term clinical outcomes of oral antidiabetic drugs as fixed‐dose combinations: A nationwide retrospective cohort study
  Sang‐Jun Cho, In‐Sun Oh, Han Eol Jeong, Young Min Cho, Yul Hwangbo, Oriana Hoi Yun Yu, Ju‐Young Shin
  Diabetes, Obesity and Metabolism.2022; 24(10): 2051.     CrossRef
• Randomized Clinical Trial on Efficacy of Empagliflozin Versus Sitagliptin, In Addition to Metformin in Type 2 Diabetic Patients
  Muaz Mubashir, Mazhar Ahmed, Hassan Atique, Ahmed Wassan, Mehdi Naqvi, Muneeb Ullah
  Cureus.2022;[Epub]     CrossRef
• The Mediating Effect of Acceptance Action in the Relationship between Diabetes Distress and Self-stigma among Old Adults with Diabetes in South Korea
  Hyesun Kim, Kawoun Seo
  Journal of Korean Academy of Community Health Nursing.2022; 33(4): 446.     CrossRef
• Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
  Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
  Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
• Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
  Linong Ji, Jianhua Ma, Weiping Lu, Jingdong Liu, Jiao’e Zeng, Jialin Yang, Wei Li, Xiuzhen Zhang, Xinhua Xiao, Gen Takayanagi, Yi Wang
  Journal of Diabetes Investigation.2021; 12(4): 537.     CrossRef
• Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
  Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
  Diabetes & Metabolism Journal.2021; 45(2): 260.     CrossRef
• Blood glucose levels and bodyweight change after dapagliflozin administration
  Hyunah Kim, Seung‐Hwan Lee, Hyunyong Lee, Hyeon Woo Yim, Jae‐Hyoung Cho, Kun‐Ho Yoon, Hun‐Sung Kim
  Journal of Diabetes Investigation.2021; 12(9): 1594.     CrossRef
• Effects of liraglutide combined with metformin and Diamicron on glucose–lipid metabolism and islet β-cell function in elderly patients with type 2 diabetes mellitus
  Chunzhi Zhao, Xing Li, Jianhua Ma, Zhengtai Zhu, Hua Li, Fangli Lou, Yuefang Zhai, Hui Chen, Shujun Xiao, Qinhui Peng, Huilian Hua, Qing Zhang, Fangyong Lou
  All Life.2021; 14(1): 333.     CrossRef
• Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial
  Ling Qu, Xiaochun Liang, Guoqing Tian, Gaili Zhang, Qunli Wu, Xiumei Huang, Yazhong Cui, Yuling Liu, Zhufang Shen, Changqing Xiao, Yingfen Qin, Heng Miao, Yongyan Zhang, Ziling Li, Shandong Ye, Xuezhi Zhang, Jing Yang, Guiwen Cao, Yi Li, Gangyi Yang, Ji H
  Diabetes Care.2021; 44(6): 1324.     CrossRef
• Clinical Impact of Combination Therapy in Diabetic Neuropathy and Nephropathy
  Harmeet Kaur, Arvinder Kaur, Pankaj Kumar Prashar, Anamika Gautam, Ankita Sood, Sachin Kumar Singh, Monica Gulati, Narendra Kumar Pandey, Bimlesh Kumar
  Research Journal of Pharmacy and Technology.2021; : 3471.     CrossRef
• Effect of Voluntary Participation on Mobile Health Care in Diabetes Management: Randomized Controlled Open-Label Trial
  Da Young Lee, Seung-Hyun Yoo, Kyong Pil Min, Cheol-Young Park
  JMIR mHealth and uHealth.2020; 8(9): e19153.     CrossRef
• Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
  Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
  Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
• Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
  Jeong Mi Kim, Sang Soo Kim, Jong Ho Kim, Mi Kyung Kim, Tae Nyun Kim, Soon Hee Lee, Chang Won Lee, Ja Young Park, Eun Sook Kim, Kwang Jae Lee, Young Sik Choi, Duk Kyu Kim, In Joo Kim
  Diabetes & Metabolism Journal.2020; 44(1): 67.     CrossRef
• Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes
  Sang Ouk Chin, In Gyoon Ha, Sang Youl Rhee, Su Jin Jeong, Suk Chon, Sung Hoon Kim, Kyu Jeung Ahn, Sei Hyun Baik, Yongsoo Park, Moon Suk Nam, Kwan Woo Lee, Jeong Taek Woo
  International Journal of Endocrinology.2020; 2020: 1.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus
  Jae Hyun Bae, Hyung Jin Choi, Kang Ik Kevin Cho, Lee Kyung Kim, Jun Soo Kwon, Young Min Cho
  Diabetes & Metabolism Journal.2020; 44(2): 248.     CrossRef

• Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects

  
  Hyounggyoon Yoo, Yun Kim, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee
  Drug Design, Development and Therapy.2020; Volume 14: 5179.     CrossRef
• Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes
  Yun Kyung Cho, Jiwoo Lee, Yu Mi Kang, Jee Hee Yoo, Joong-Yeol Park, Chang Hee Jung, Woo Je Lee, Tatsuo Shimosawa
  PLOS ONE.2019; 14(8): e0220667.     CrossRef
• Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double‐blind, non‐inferiority trial
  Yonghyun Kim, Eun Seok Kang, Hak Chul Jang, Dong Jun Kim, Taekeun Oh, Eun Sook Kim, Nan‐Hee Kim, Kyung Mook Choi, Sung‐Rae Kim, JiYoung You, Se‐Jin Kim, Moon‐Kyu Lee
  Diabetes, Obesity and Metabolism.2019; 21(3): 631.     CrossRef
• Pharmacotherapy of Diabetes Focused on Stroke
  Young-Sang Lyu, Jin-Hwa Kim, Sang-Yong Kim
  Journal of the Korean Neurological Association.2019; 37(3): 235.     CrossRef
• Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86)
  Hannah Seok, Tae Seo Sohn
  Diabetes & Metabolism Journal.2019; 43(4): 545.     CrossRef
• Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
  Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam, Eun Seok Kang
  Diabetes Care.2019; 42(11): 2057.     CrossRef
• Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
  Tae Jung Oh, Jae Myung Yu, Kyung Wan Min, Hyun Shik Son, Moon Kyu Lee, Kun Ho Yoon, Young Duk Song, Joong Yeol Park, In Kyung Jeong, Bong Soo Cha, Yong Seong Kim, Sei Hyun Baik, In Joo Kim, Doo Man Kim, Sung Rae Kim, Kwan Woo Lee, Jeong Hyung Park, In Kyu
  Diabetes & Metabolism Journal.2019; 43(3): 276.     CrossRef
• 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
  Mee Kyoung Kim, Seung-Hyun Ko, Bo-Yeon Kim, Eun Seok Kang, Junghyun Noh, Soo-Kyung Kim, Seok-O Park, Kyu Yeon Hur, Suk Chon, Min Kyong Moon, Nan-Hee Kim, Sang Yong Kim, Sang Youl Rhee, Kang-Woo Lee, Jae Hyeon Kim, Eun-Jung Rhee, SungWan Chun, Sung Hoon Yu
  Diabetes & Metabolism Journal.2019; 43(4): 398.     CrossRef
• Medical Big Data Is Not Yet Available: Why We Need Realism Rather than Exaggeration
  Hun-Sung Kim, Dai-Jin Kim, Kun-Ho Yoon
  Endocrinology and Metabolism.2019; 34(4): 349.     CrossRef
• Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association
  Sang Youl Rhee
  The Journal of Korean Diabetes.2018; 19(1): 15.     CrossRef
• Glucose Control in Intensive Care Unit Patients: Recent Updates
  Sang Youl Rhee
  Journal of Neurocritical Care.2018; 11(2): 81.     CrossRef
• Educational Strategies for Insulin Injection Therapy in Elderly Diabetic Patients
  Eun Chong Shin
  The Journal of Korean Diabetes.2018; 19(2): 101.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
  Hyun Jin Kim
  The Journal of Korean Diabetes.2018; 19(1): 35.     CrossRef
• Fifty Years of Compassionate Care and Harmonious Collaboration of the Korean Diabetes Association: The 50th Anniversary of Korean Diabetes Association
  Jong Chul Won, Eun-Jung Rhee, Hyung Joon Yoo
  Diabetes & Metabolism Journal.2018; 42(6): 475.     CrossRef
• Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
  Kyung‐Ah Han, Suk Chon, Choon Hee Chung, Soo Lim, Kwan‐Woo Lee, SeiHyun Baik, Chang Hee Jung, Dong‐Sun Kim, Kyong Soo Park, Kun‐Ho Yoon, In‐Kyu Lee, Bong‐Soo Cha, Taishi Sakatani, Sumi Park, Moon‐Kyu Lee
  Diabetes, Obesity and Metabolism.2018; 20(10): 2408.     CrossRef
• Monotherapy in Patients with Type 2 Diabetes Mellitus
  Sang Youl Rhee, Hyun Jin Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 349.     CrossRef
• Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017
  Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
  The Korean Journal of Internal Medicine.2017; 32(6): 967.     CrossRef
• New anti-diabetic agents
  Doo-Man Kim
  Journal of the Korean Medical Association.2017; 60(12): 992.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
  Hyun Jin Kim, Seok O Park, Seung-Hyun Ko, Sang Youl Rhee, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Byung-Wan Lee, Jin Hwa Kim, Kyung Mook Choi
  Diabetes & Metabolism Journal.2017; 41(6): 423.     CrossRef
• Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
  Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
  Diabetes & Metabolism Journal.2017; 41(5): 367.     CrossRef

Citations

Citations to this article as recorded by  

• The relationship of Growth differentiation factor-15 with renal damage and dyslipidemia in non-albuminuric and albuminuric Type-2 Diabetes Mellitus
  Hasan Esat Yücel, Bilal İlanbey
  Medical Science and Discovery.2022; 9(6): 334.     CrossRef
• Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis
  Alexander Hodkinson, Dialechti Tsimpida, Evangelos Kontopantelis, Martin K Rutter, Mamas A Mamas, Maria Panagioti
  BMJ.2022; : e067731.     CrossRef
• The Cytokine Growth Differentiation Factor-15 and Skeletal Muscle Health: Portrait of an Emerging Widely Applicable Disease Biomarker
  Boel De Paepe
  International Journal of Molecular Sciences.2022; 23(21): 13180.     CrossRef
• Biomarkers of subclinical atherosclerosis in patients with psoriasis
  Hannah Kaiser, Xing Wang, Amanda Kvist-Hansen, Martin Krakauer, Peter Michael Gørtz, Benjamin D. McCauley, Lone Skov, Christine Becker, Peter Riis Hansen
  Scientific Reports.2021;[Epub]     CrossRef
• Growth differentiation factor-15 regulates oxLDL-induced lipid homeostasis and autophagy in human macrophages
  Kathrin Ackermann, Gabriel A. Bonaterra, Ralf Kinscherf, Anja Schwarz
  Atherosclerosis.2019; 281: 128.     CrossRef

Citations

Citations to this article as recorded by  

• Effect of a 6-Week Carbohydrate-Reduced High-Protein Diet on Levels of FGF21 and GDF15 in People With Type 2 Diabetes
  Michael M Richter, Mads N Thomsen, Mads J Skytte, Sasha A S Kjeldsen, Amirsalar Samkani, Jan Frystyk, Faidon Magkos, Jens J Holst, Sten Madsbad, Thure Krarup, Steen B Haugaard, Nicolai J Wewer Albrechtsen
  Journal of the Endocrine Society.2024;[Epub]     CrossRef
• Serum Growth Differentiation Factor 15 Levels Predict the Incidence of Frailty among Patients with Cardiometabolic Diseases
  Kazuhito Oba, Joji Ishikawa, Yoshiaki Tamura, Yasunori Fujita, Masafumi Ito, Ai Iizuka, Yoshinori Fujiwara, Remi Kodera, Kenji Toyoshima, Yuko Chiba, Masashi Tanaka, Atsushi Araki
  Gerontology.2024; : 1.     CrossRef
• Growth differentiation factor 15 and malnutrition in older adults
  Nazanin Rostami, Blanca Fabre-Estremera, Antonio Buño-Soto, José R Banegas, Fernando Rodríguez-Artalejo, Rosario Ortolá
  The Journal of nutrition, health and aging.2024; 28(6): 100230.     CrossRef
• Evaluation of the relation between subclinical systolic dysfunction defined by four-dimensional speckle-tracking echocardiography and growth differentiation factor-15 levels in patients with acromegaly
  Busra Firlatan, Ugur Nadir Karakulak, Vedat Hekimsoy, Burcin Gonul Iremli, Incilay Lay, Deniz Yuce, Selcuk Dagdelen, Giray Kabakci, Tomris Erbas
  Hormones.2024;[Epub]     CrossRef
• Exploration of meteorin-like peptide (metrnl) predictors in type 2 diabetic patients: the potential role of irisin, and other biochemical parameters
  Yaser Khajebishak, Amir Hossein Faghfouri, Ali Soleimani, Sadra Madani, Laleh Payahoo
  Hormone Molecular Biology and Clinical Investigation.2023; 44(2): 127.     CrossRef
• Relationship between meteorin-like peptide (Metrnl) serum levels and inflammatory cytokines, oxidative stress biomarkers and body composition parameters in type 2 diabetes patients
  Yaser Khajebishak, Sadra Madani, Amir Hossein Faghfouri, Ali Soleimani, Sara Ilaei, Said Peyrovi, Laleh Payahoo
  Nutrition & Food Science.2023; 53(5): 861.     CrossRef
• Effects of acute exercise and exercise training on plasma GDF15 concentrations and associations with appetite and cardiometabolic health in individuals with overweight or obesity – A secondary analysis of a randomized controlled trial
  Jonas Salling Quist, Anders Bue Klein, Kristine Færch, Kristine Beaulieu, Mads Rosenkilde, Anne Sofie Gram, Anders Sjödin, Signe Torekov, Bente Stallknecht, Christoffer Clemmensen, Martin Bæk Blond
  Appetite.2023; 182: 106423.     CrossRef
• Significant increase of serum extracellular vesicle-packaged growth differentiation factor 15 in type 2 diabetes mellitus: a cross-sectional study
  Wen Zhao, Xinwei Li, Xinxin Li, Lu Peng, Yu Li, Yunhui Du, Jianxun He, Yanwen Qin, Huina Zhang
  European Journal of Medical Research.2023;[Epub]     CrossRef
• Association between growth differentiation factor 15 levels and gestational diabetes mellitus: A combined analysis
  Yi-Cheng Lu, Song-Liang Liu, Yu-Shan Zhang, Fei Liang, Xiao-Yan Zhu, Yue Xiao, Jing Wang, Cong Ding, Sudipta Banerjee, Jie-Yun Yin, Qiu-Ping Ma
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight
  Song-Yang Zhang, Kyla Bruce, Zahra Danaei, Rosa J.W. Li, Daniel R. Barros, Rachel Kuah, Yu-Mi Lim, Laura H. Mariani, David Z. Cherney, Jennifer F.M. Chiu, Heather N. Reich, Tony K.T. Lam
  Cell Metabolism.2023; 35(5): 875.     CrossRef
• Growth differentiation factor 15 (GDF-15) in endocrinology
  Pedro Iglesias, Ramona A. Silvestre, Juan J. Díez
  Endocrine.2023; 81(3): 419.     CrossRef
• Identification of biomarkers for glycaemic deterioration in type 2 diabetes
  Roderick C. Slieker, Louise A. Donnelly, Elina Akalestou, Livia Lopez-Noriega, Rana Melhem, Ayşim Güneş, Frederic Abou Azar, Alexander Efanov, Eleni Georgiadou, Hermine Muniangi-Muhitu, Mahsa Sheikh, Giuseppe N. Giordano, Mikael Åkerlund, Emma Ahlqvist, A
  Nature Communications.2023;[Epub]     CrossRef
• Metabolic syndrome and Growth Differentiation Factor 15 in older adults
  Adrián Carballo-Casla, Esther García-Esquinas, Antonio Buño-Soto, Ellen A. Struijk, Esther López-García, Fernando Rodríguez-Artalejo, Rosario Ortolá
  GeroScience.2022; 44(2): 867.     CrossRef
• Associations between GDF15 Levels and Pre-Diabetes in Non-Obese Subjects
  Hao-Chang Hung, Hung-Tsung Wu, Ching-Han Lin, Hsuan-Wen Chou, Horng-Yih Ou, Chih-Jen Chang
  Journal of Investigative Medicine.2022; 70(1): 79.     CrossRef
• Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study
  Dipayan Roy, Purvi Purohit, Anupama Modi, Manoj Khokhar, Ravindra Kumar Gayaprasad Shukla, Ramkaran Chaudhary, Shrimanjunath Sankanagoudar, Praveen Sharma
  Current Diabetes Reviews.2022;[Epub]     CrossRef
• Growth Differentiation Factor 15 Protects SH-SY5Y Cells From Rotenone-Induced Toxicity by Suppressing Mitochondrial Apoptosis
  Peizheng Li, Hongbo Lv, Bohan Zhang, Ruonan Duan, Xiufang Zhang, Pengfei Lin, Chengyuan Song, Yiming Liu
  Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
• GDF-15 as a Therapeutic Target of Diabetic Complications Increases the Risk of Gallstone Disease: Mendelian Randomization and Polygenic Risk Score Analysis
  Lili Yu, Yajing Zhou, Lijuan Wang, Xuan Zhou, Jing Sun, Jiarui Xiao, Xiaolin Xu, Susanna C. Larsson, Shuai Yuan, Xue Li
  Frontiers in Genetics.2022;[Epub]     CrossRef
• Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity
  Mohamed Asrih, Flore Sinturel, Richard Dubos, Idris Guessous, Zoltan Pataky, Charna Dibner, François R Jornayvaz, Karim Gariani
  Endocrine Connections.2022;[Epub]     CrossRef
• Raised circulating soluble growth differentiation factor 15 is negatively associated with testosterone level in hypogonadic men with type 2 diabetes
  Yufeng Mei, Yongnan Lyu, Juan Le, Di Li, Hang Liu, Zhiming Zhao, Yan Li
  Diabetes/Metabolism Research and Reviews.2022;[Epub]     CrossRef
• NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice
  Matthew J Jennings, Alexia Kagiava, Leen Vendredy, Emily L Spaulding, Marina Stavrou, Denisa Hathazi, Anika Grüneboom, Vicky De Winter, Burkhard Gess, Ulrike Schara, Oksana Pogoryelova, Hanns Lochmüller, Christoph H Borchers, Andreas Roos, Robert W Burges
  Brain.2022; 145(11): 3999.     CrossRef
• Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure
  Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Athanasios Alexiou, Marios Papadakis, Eman Hassan Nadwa, Sarah M. Albogami, Mohammed Alorabi, Hebatallah M. Saad, Gaber El‐Saber Batiha
  Journal of Diabetes.2022; 14(12): 806.     CrossRef
• GDF15 is an exercise-induced hepatokine regulated by glucagon and insulin in humans
  Peter Plomgaard, Jakob S. Hansen, Logan K. Townsend, Anders Gudiksen, Niels H. Secher, Jens O. Clemmesen, Rene K. Støving, Jens P. Goetze, David C. Wright, Henriette Pilegaard
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• A study of serum growth differentiation factor 15 in Indian women with and without gestational diabetes mellitus in the third trimester of pregnancy and its association with pro-inflammatory markers and glucose metabolism
  Sudipta Banerjee, Rana Bhattacharjee, Amitabh Sur, Pieu Adhikary, Subhankar Chowdhury
  Diabetology International.2021; 12(3): 254.     CrossRef
• Growth Differentiation Factor 15 is a Cancer Cell-Induced Mitokine That Primes Thyroid Cancer Cells for Invasiveness
  Yea Eun Kang, Jin Man Kim, Mi Ae Lim, Seong Eun Lee, Shinae Yi, Jung Tae Kim, Chan Oh, Lihua Liu, Yanli Jin, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Jeong Ho Lee, Hyun Jung Kim, Hyun Yong Koh, Sangmi Jun, Sun Wook Cho, Minho Shong, Bon Seok Koo
  Thyroid.2021; 31(5): 772.     CrossRef
• The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?
  Samuel N. Breit, David A. Brown, Vicky Wang-Wei Tsai
  Annual Review of Physiology.2021; 83(1): 127.     CrossRef
• Associations of GDF-15 and GDF-15/adiponectin ratio with odds of type 2 diabetes in the Chinese population
  Xiaoying Wu, Wenting Xuan, Lili You, Hong Lian, Feng Li, Xiaoyun Zhang, Qingyu Chen, Kan Sun, Chaogang Chen, Mingtong Xu, Yan Li, Li Yan, Xiuwei Zhang, Meng Ren
  Endocrine.2021; 72(2): 423.     CrossRef
• Decreased serum growth differentiation factor 15 levels after lifestyle intervention in patients with newly diagnosed type 2 diabetes mellitus
  Xingxing He, Jiaorong Su, Xiaojing Ma, Jingyi Lu, Yufei Wang, Jun Yin, Yuqian Bao, Gang Hu, Jian Zhou
  Obesity Medicine.2021; 24: 100345.     CrossRef
• The anti-diabetic effects of NAG-1/GDF15 on HFD/STZ-induced mice
  Pattawika Lertpatipanpong, Jaehak Lee, Ilju Kim, Thomas Eling, Seung Yeon Oh, Je Kyung Seong, Seung Joon Baek
  Scientific Reports.2021;[Epub]     CrossRef
• The Regulation of Circulating Hepatokines by Fructose Ingestion in Humans
  Michael M Richter, Peter Plomgaard
  Journal of the Endocrine Society.2021;[Epub]     CrossRef
• GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease
  Dongdong Wang, Emily A. Day, Logan K. Townsend, Djordje Djordjevic, Sebastian Beck Jørgensen, Gregory R. Steinberg
  Nature Reviews Endocrinology.2021; 17(10): 592.     CrossRef
• High Fat, High Sugar Diet and DJOS Bariatric Surgery Influence Plasma Levels of Fetuin-B, Growth Differentiation Factor-15, and Pentraxin 3 in Diet-Induced Obese Sprague–Dawley Rats
  Jakub Poloczek, Monika Tarnawska, Elżbieta Chełmecka, Piotr Łaszczyca, Janusz Gumprecht, Dominika Stygar
  Nutrients.2021; 13(10): 3632.     CrossRef
• Serum growth differentiation factor 15 level is associated with muscle strength and lower extremity function in older patients with cardiometabolic disease
  Kazuhito Oba, Joji Ishikawa, Yoshiaki Tamura, Yasunori Fujita, Masafumi Ito, Ai Iizuka, Yoshinori Fujiwara, Remi Kodera, Ayumi Toba, Kenji Toyoshima, Yuko Chiba, Seijiro Mori, Masashi Tanaka, Hideki Ito, Kazumasa Harada, Atsushi Araki
  Geriatrics & Gerontology International.2020; 20(10): 980.     CrossRef
• Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach
  Axel C. Carlsson, Christoph Nowak, Lars Lind, Carl Johan Östgren, Fredrik H. Nyström, Johan Sundström, Juan Jesus Carrero, Ulf Riserus, Erik Ingelsson, Tove Fall, Johan Ärnlöv
  Upsala Journal of Medical Sciences.2020; 125(1): 37.     CrossRef
• Elevated Plasma Growth and Differentiation Factor 15 Is Associated With Slower Gait Speed and Lower Physical Performance in Healthy Community-Dwelling Adults
  Richard D Semba, Marta Gonzalez-Freire, Toshiko Tanaka, Angelique Biancotto, Pingbo Zhang, Michelle Shardell, Ruin Moaddel, Luigi Ferrucci, Anne Newman
  The Journals of Gerontology: Series A.2020; 75(1): 175.     CrossRef
• Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review
  Alexander E. Berezin, Alexander A. Berezin
  Diabetes Therapy.2020; 11(6): 1271.     CrossRef
• Deterioration of Sleep Quality According to Glycemic Status
  Myung Haeng Hur, Mi-Kyoung Lee, Kayeon Seong, Jun Hwa Hong
  Diabetes & Metabolism Journal.2020; 44(5): 679.     CrossRef
• Effects of plant and animal high protein diets on immune-inflammatory biomarkers: A 6-week intervention trial
  Mariya Markova, Liselot Koelman, Silke Hornemann, Olga Pivovarova, Stephanie Sucher, Juergen Machann, Natalia Rudovich, Ralph Thomann, Rosemarie Schneeweiss, Sascha Rohn, Andreas F.H. Pfeiffer, Krasimira Aleksandrova
  Clinical Nutrition.2020; 39(3): 862.     CrossRef
• Effect of sleeve gastrectomy on plasma growth differentiation factor-15 (GDF15) in human
  Ponnie Robertlee Dolo, Libin Yao, Peng Peng Liu, Jason Widjaja, Song Meng, Chao Li, Xiaocheng Zhu
  The American Journal of Surgery.2020; 220(3): 725.     CrossRef
• Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers
  Alexander E. Berezin
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(2): 995.     CrossRef
• Effect of bariatric surgery on plasma GDF15 in humans
  Maximilian Kleinert, Kirstine N. Bojsen-Møller, Nils B. Jørgensen, Maria S. Svane, Christoffer Martinussen, Bente Kiens, Jørgen F.P. Wojtaszewski, Sten Madsbad, Erik A. Richter, Christoffer Clemmensen
  American Journal of Physiology-Endocrinology and Metabolism.2019; 316(4): E615.     CrossRef
• Regulation of Systemic Glucose Homeostasis by T Helper Type 2 Cytokines
  Yea Eun Kang, Hyun Jin Kim, Minho Shong
  Diabetes & Metabolism Journal.2019; 43(5): 549.     CrossRef
• GDF15 reflects beta cell function in obese patients independently of the grade of impairment of glucose metabolism
  M.H. Schernthaner-Reiter, B.K. Itariu, M. Krebs, M. Promintzer-Schifferl, T.M. Stulnig, A. Tura, C.H. Anderwald, M. Clodi, B. Ludvik, G. Pacini, A. Luger, G. Vila
  Nutrition, Metabolism and Cardiovascular Diseases.2019; 29(4): 334.     CrossRef
• Growth differentiation factor 15: A novel biomarker with high clinical potential
  Stéphanie Desmedt, Valérie Desmedt, Leen De Vos, Joris R. Delanghe, Reinhart Speeckaert, Marijn M. Speeckaert
  Critical Reviews in Clinical Laboratory Sciences.2019; 56(5): 333.     CrossRef
• Hepatokines—a novel group of exercise factors
  Cora Weigert, Miriam Hoene, Peter Plomgaard
  Pflügers Archiv - European Journal of Physiology.2019; 471(3): 383.     CrossRef
• Association between MIC-1 and Type 2 Diabetes: A Combined Analysis
  Jianan Lu, Yue Zhang, Xingxuan Dong, Jiawen Lu, Chen Zhang, Jieyu Liu, Qingzhou Yu, Haoyue Teng, Qingkui Yao, Jieyun Yin, Liqiang Qin
  Disease Markers.2019; 2019: 1.     CrossRef
• The mitochondrial unfolded protein response and mitohormesis: a perspective on metabolic diseases
  Hyon-Seung Yi, Joon Young Chang, Minho Shong
  Journal of Molecular Endocrinology.2018; 61(3): R91.     CrossRef
• Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases
  Ana Luisa Cardoso, Adelaide Fernandes, Juan Antonio Aguilar-Pimentel, Martin Hrabě de Angelis, Joana Ribeiro Guedes, Maria Alexandra Brito, Saida Ortolano, Giovambattista Pani, Sophia Athanasopoulou, Efstathios S. Gonos, Markus Schosserer, Johannes Grilla
  Ageing Research Reviews.2018; 47: 214.     CrossRef
• Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes
  Ju Hee Lee, Yea Eun Kang, Ji Min Kim, Sorim Choung, Kyong Hye Joung, Hyun Jin Kim, Bon Jeong Ku
  Diabetes Research and Clinical Practice.2018; 135: 7.     CrossRef
• Growth differentiation factor 15 predicts advanced fibrosis in biopsy‐proven non‐alcoholic fatty liver disease
  Bo Kyung Koo, Sung Hee Um, Dong Soo Seo, Sae Kyung Joo, Jeong Mo Bae, Jeong Hwan Park, Mee Soo Chang, Jung Ho Kim, Jieun Lee, Won‐Il Jeong, Won Kim
  Liver International.2018; 38(4): 695.     CrossRef
• Serum Growth Differentiation Factor 15 in Parkinson Disease
  Xiaomei Yao, Dong Wang, Lei Zhang, Lingling Wang, Zhenxiang Zhao, Si Chen, Xiaotang Wang, Tao Yue, Yiming Liu
  Neurodegenerative Diseases.2017; 17(6): 251.     CrossRef
• GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury
  Hyo Kyun Chung, Jung Tae Kim, Hyeon-Woo Kim, Minjoo Kwon, So Yeon Kim, Minho Shong, Koon Soon Kim, Hyon-Seung Yi
  Scientific Reports.2017;[Epub]     CrossRef
• Growth differentiation factor 15 as a predictor of adverse renal outcomes in patients with immunoglobulin A nephropathy
  Ki R. Na, Yoo H. Kim, Hyo K. Chung, Min‐Kyung Yeo, Young R. Ham, Jin Y. Jeong, Koon S. Kim, Kang W. Lee, Dae E. Choi
  Internal Medicine Journal.2017; 47(12): 1393.     CrossRef
• GDF15 contributes to radiation-induced senescence through the ROS-mediated p16 pathway in human endothelial cells
  Hyejin Park, Chun-Ho Kim, Jae-Hoon Jeong, Myungjin Park, Kwang Seok Kim
  Oncotarget.2016; 7(9): 9634.     CrossRef
• GDF-15 and Hepcidin Levels in Nonanemic Patients with Impaired Glucose Tolerance
  Mehmet Muhittin Yalcin, Alev Eroglu Altinova, Mujde Akturk, Ozlem Gulbahar, Emre Arslan, Damla Ors Sendogan, Ilhan Yetkin, Fusun Balos Toruner
  Journal of Diabetes Research.2016; 2016: 1.     CrossRef
• Cardiac‐Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers
  Colleen M. Dewey, Kathryn M. Spitler, Jessica M. Ponce, Duane D. Hall, Chad E. Grueter
  Journal of the American Heart Association.2016;[Epub]     CrossRef
• Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study
  Serdar Farhan, Matthias K. Freynhofer, Ivan Brozovic, Veronika Bruno, Birgit Vogel, Ioannis Tentzeris, Sabina Baumgartner-Parzer, Kurt Huber, Alexandra Kautzky-Willer
  Cardiovascular Diabetology.2016;[Epub]     CrossRef
• Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia
  Ji Min Kim, Min Kyung Back, Hyon-Seung Yi, Kyong Hye Joung, Hyun Jin Kim, Bon Jeong Ku
  Diabetes & Metabolism Journal.2016; 40(1): 70.     CrossRef
• Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
  Min Young Shin, Ji Min Kim, Yea Eun Kang, Min Kyeong Kim, Kyong Hye Joung, Ju Hee Lee, Koon Soon Kim, Hyun Jin Kim, Bon Jeong Ku, Minho Shong
  Journal of Korean Medical Science.2016; 31(9): 1413.     CrossRef
• Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose
  Ying Cui, Wen Chen, Jinfeng Chi, Lei Wang
  Medical Science Monitor.2016; 22: 4699.     CrossRef
• Letter: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J2014;38:472-9)
  Bo Kyung Koo
  Diabetes & Metabolism Journal.2015; 39(1): 82.     CrossRef
• Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment
  Jun Hwa Hong, Yeon-Kyung Choi, Byong-Keol Min, Kang Seo Park, Kayeon Seong, In Kyu Lee, Jung Guk Kim
  Diabetes Research and Clinical Practice.2015; 109(1): 64.     CrossRef
• Response: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J2014;38:472-9)
  Jun Hwa Hong, Bon Jeong Ku, Minho Shong
  Diabetes & Metabolism Journal.2015; 39(1): 84.     CrossRef
• Is GDF15 a Novel Biomarker to Predict the Development of Prediabetes or Diabetes?
  Kyu Yeon Hur
  Diabetes & Metabolism Journal.2014; 38(6): 437.     CrossRef